Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause pain and discomfort, can block blood flow, may interfere with cancer therapy, and can occasionally be life-threatening.
The purpose of this study is to determine if a daily injection of a blood-thinner, dalteparin, for three months can safely and effectively reduce the frequency of blood clots in patients at increased risk.
Dalteparin sodium (Fragmin) 5000IU sq (injections just below the skin) once daily vs. no study drug
Four (Staff will try to schedule visits to coincide with regular oncology clinic visits)
200 Duke patients
Nicole M. Kuderer, MD, and Gary H. Lyman, MD
For more information, contact Phillis Scott at 919-668-1094.